0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
JAMA Patient Page |

Gaucher Disease FREE

John L. Zeller, MD, PhD, Writer; Alison E. Burke, MA, Illustrator; Richard M. Glass, MD, Editor
JAMA. 2007;298(11):1358. doi:10.1001/jama.298.11.1358.
Text Size: A A A
Published online

Gaucher disease is a chronic, progressive, inherited disorder named for the French physician who first described it. It is caused by a deficiency of a specific enzyme called glucocerebrosidase. This enzyme breaks down and recycles certain lipids (fats). In people with Gaucher disease, these lipids, glucocerebrosides, accumulate within cells and interfere with the normal functioning of various organs (liver, spleen, lungs, bone marrow, and brain). The disease is classified into 3 types. In type 1, there is no brain involvement. It is found in adults, accounts for 95% of all cases, and can sometimes have no symptoms. The type 2 condition is uncommon and severe. Brain damage can be extensive. Children usually die by 2 years of age. Type 3 occurs in children and adolescents. It tends to be chronic and slowly progressive and the central nervous system is affected.

It is estimated that approximately 1 in 40 000 to 60 000 persons in the general population has Gaucher disease, or about 10 000 people worldwide. It is the most common disorder in a group of more than 40 diseases classified as lysosomal storage disorders (LSDs). Grouped together, LSDs affect 1 in every 7700 babies born. The September 19, 2007, issue of JAMA includes an article about genetic screening and treatment for Gaucher disease.

RISK FACTORS

Gaucher disease may occur among every nationality and ethnic group but it is most common among Ashkenazi Jews (individuals of particular Jewish descent from Eastern or Central Europe). In this particular ethnic group, the incidence is 1 in 450 persons.

SIGNS AND SYMPTOMS

Symptoms of Gaucher disease can vary form the very mild, or even none, to severe. Bone pain or fracture is often the first symptom. Other symptoms may include

  • Skeletal abnormalities

  • Hepatomegaly (enlarged liver)

  • Splenomegaly (enlarged spleen)

  • Anemia (reduced number of red blood cells)

  • Excessive fatigue

  • Bleeding and easy bruising due to thrombocytopenia (low platelet count)

  • Mental retardation

  • Dementia

  • Pingueculae (yellow spots in the eyes)

  • Abnormal eye movements

TESTING AND TREATMENT

A blood test to measure glucocerebrosidase enzyme activity is currently used to determine whether a person has Gaucher disease or may be a carrier. With a confirmation of the diagnosis, disease management has shifted to disease-specific therapies:

  • Enzyme replacement therapy (ERT)—The goal of ERT is to provide an appropriate amount of needed enzyme.

  • Substrate reduction therapy (SRT)—The goal is to minimize the amount of production and accumulation of waste material within cells.

  • Symptom management—Treatment includes pain reduction therapies, blood transfusions, orthopedic surgery, and possible splenectomy (removal of the spleen).

  • Psychological care—Professional counseling can help patients better manage the difficulties of their disease and the lifestyle changes that might be required.

FOR MORE INFORMATION

INFORM YOURSELF

To find this and previous JAMA Patient Pages, go to the Patient Page link on JAMA's web site at http://www.jama.com. Many are available in English and Spanish.

Sources: National Gaucher Foundation, National Organization for Rare Disorders

The JAMA Patient Page is a public service of JAMA. The information and recommendations appearing on this page are appropriate in most instances, but they are not a substitute for medical diagnosis. For specific information concerning your personal medical condition, JAMA suggests that you consult your physician. This page may be photocopied noncommercially by physicians and other health care professionals to share with patients. To purchase bulk reprints, call 203/259-8724.

TOPIC: GENETIC DISORDERS

Figures

Tables

References

Letters

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Spanish Patient Pages
Supplemental Content

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles